PepGen, Inc. (NASDAQ:PEPG) Given Average Rating of “Moderate Buy” by Analysts

Shares of PepGen, Inc. (NASDAQ:PEPG) have been given a consensus rating of “Moderate Buy” by the six research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $11.60.

A number of equities analysts have weighed in on PEPG shares. HC Wainwright reissued a “buy” rating on shares of PepGen in a research report on Thursday, May 21st. Guggenheim upped their price target on shares of PepGen from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Wall Street Zen lowered shares of PepGen from a “hold” rating to a “sell” rating in a research report on Saturday. Wedbush reduced their price target on shares of PepGen from $5.00 to $4.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Finally, Oppenheimer began coverage on shares of PepGen in a research report on Wednesday, February 25th. They set an “outperform” rating and a $15.00 price target for the company.

Institutional Investors Weigh In On PepGen

Several hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. increased its position in shares of PepGen by 94.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,202 shares of the company’s stock valued at $73,000 after purchasing an additional 5,453 shares during the last quarter. Heights Capital Management Inc. purchased a new stake in shares of PepGen during the 3rd quarter valued at about $46,000. Burkehill Global Management LP purchased a new stake in shares of PepGen during the 3rd quarter valued at about $46,000. Jefferies Financial Group Inc. purchased a new stake in shares of PepGen during the 4th quarter valued at about $89,000. Finally, Militia Capital Partners LP purchased a new stake in shares of PepGen during the 3rd quarter valued at about $72,000. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Stock Performance

Shares of NASDAQ:PEPG opened at $1.47 on Tuesday. PepGen has a fifty-two week low of $1.01 and a fifty-two week high of $7.80. The business has a 50-day simple moving average of $2.06 and a two-hundred day simple moving average of $4.45. The firm has a market cap of $101.68 million, a price-to-earnings ratio of -0.84 and a beta of 1.93.

PepGen (NASDAQ:PEPG) last issued its earnings results on Tuesday, May 12th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. As a group, research analysts predict that PepGen will post -1.18 earnings per share for the current year.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).